Introduction
Introduction
Nitric oxide regulates diverse physiological and pathological responses in the cardiovascular system [1] [2] [3] [2, 4] [5] . Furthermore, iNOS contains tightly bound Ca ϩϩ /calmodulin that does not dissociate in resting cells, and it is constitutively active once synthesized [1, 6] . This has lead to the prevailing view that iNOS generates unregulated high output nitric oxide (given sufficient substrate and cofactors) until the protein is degraded [1, [4] [5] [6] . Recent studies have suggested some mechanisms for post-translational regulation of iNOS that affect basal activity or protein expression. For example, iNOS dimerization and activity are inhibited by S-nitrosylation [7] and interaction with kalirin or NAP110 [4] but enhanced by interaction with hsp90 [8] . iNOS activity is also reduced by sequestration in aggresomes [9] , and its degradation is enhanced by interaction with caveolin-1 [4] . The phosphorylation sites that are important in regulating eNOS activity [1, 2] and decreased activity [10] and phosphorylation of iNOS at Y 1055 by Src results in increased iNOS half-life [11] . [12] [13] [14] , suggesting a novel mode of acute post-translational regulation of iNOS that fundamentally differs from known mechanisms. Indeed, we discovered that B1R stimulation activated the extracellular signal-regulated kinase (ERK) which phosphorylated iNOS on Ser 745 , leading to a 2.5 to 5-fold further increase in nitric oxide production over basal activity [15] . More recently, platelets were found to constitutively express iNOS and platelet agonists at low doses (e.g. thrombin) acutely stimulated iNOS-mediated nitric oxide production to enhance platelet secretion and aggregation [16] . (3,5-dibromo-4 [3,4-d] [3, 17] .
. Three distinct isoforms of nitric oxide synthase (NOS) produce nitric oxide from the precursor amino acid L-Arg. The constitutively expressed endothelial and neuronal NOS (eNOS and nNOS) have low basal activity that is enhanced by receptor stimulation leading to increased intracellular calcium, phosphorylation at key residues and/or altered interactions with regulatory proteins

. In contrast, inducible NOS (iNOS) is not constitutively expressed in most cells and the regulation of its activity is considered to be primarily at the level of transcription and expression in response to cytokines and inflammatory mediators
are not conserved in iNOS and its regulation by phosphorylation has not been well studied. Recently it was reported that co-transfection of iNOS and activated Src results in increased phosphorylation of iNOS at Tyr
We found that activation of kinin B1 receptors (B1Rs) by peptide agonist or angiotensin converting enzyme (ACE) inhibitors led to generation of iNOS-derived high output nitric oxide in cytokinepretreated human lung microvascular endothelial cells (HLMVEC)
These findings indicate a novel mode of acute activation of iNOS via G protein coupled receptor (GPCR)-mediated signalling pathways that are still to be delineated. We undertook the present study to investigate the upstream signal transduction pathway and mitogen activated protein kinase (MAPK) components activated by B1R stimulation that leads to post-translational activation of iNOS-dependent high-output nitric oxide. Here we show that B1R-mediated activation of iNOS requires G␣i and ␤␥-dependent activation of Src, Raf, Ras, MAPK/ ERK kinase (MEK) and ERK. This newly described signalling pathway for high output nitric oxide production may play an important role in the development of vascular inflammation.
Materials and methods
Materials
-hydroxyphenyl)methylene]-2-indolinone (Raf kinase inhibitor), Ste-MPKKKPTPIQLNP-NH2 (ERK activation inhibitor peptide I), 2Ј-Amino-3Ј-methoxyflavone (PD 98059), 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo
Measurement of nitric oxide production
For direct measurement of nitric oxide generation in real time, a porphyrinic microsensor was used as described [12, 18] (Fig. 3A) .
and did not increase after cytokine treatment (Fig. 2B and C). Finally, nNOS protein was undetectable by Western analysis in control or cytokine-treated HLMVEC and nitric oxide production was unaffected by a specific nNOS inhibitor (not shown). Taken together, the above data show that B1R-dependent nitric oxide production in cytokine-treated HLMVEC is due to activation of iNOS. To further prove that B1Rs can activate iNOS, their cDNAs were transfected into control HLMVEC or HEK293 cells. Transfection of iNOS and B1Rs into HLMVEC increased basal, L-Arg-dependent nitric oxide production equivalent to that in cytokine-treated HLMVEC whereas B1R-stimulated nitric oxide production was even higher in transfected HLMVEC than after cytokine treatment (Fig. 3A). Mock transfection did not change B1R-dependent nitric oxide production in cytokine-treated HLMVEC
In HEK293 cells transfected with iNOS, basal L-Arg dependent nitric oxide output was similar to that in iNOS ϩ B1R transfected cells, while transfection of B1Rs alone gave a minor response similar to that in untransfected cells (Fig. 3B). B1R agonist did not stimulate significant nitric oxide production in untransfected HEK293 cells or cells transfected with iNOS or B1R alone, but gave a robust response in cells co-transfected with B1R and iNOS (Fig. 3B). Thus, high output nitric oxide in response to B1R agonist depends on the expression of both B1R and iNOS and transfected HEK293 cells respond similarly to cytokine-treated HLMVEC.
B1R-mediated iNOS activation requires a pertussis toxin (PTX)-sensitive G protein
B1Rs can couple to both G␣q/11 and G␣i [19] 
, but iNOS activity is not regulated by changes in intracellular Ca
ϩϩ [1, 6] 
Role of G␤␥ in B1R-mediated iNOS activation
GPCR signalling depends on activation of effectors by both G␣ and G␤␥ subunits of heterotrimeric G-proteins. To explore the role of G␤␥ subunits, HLMVEC or HEK293 cells were infected with adenovirus containing the C-terminus of the ␤-adrenergic receptor kinase (ct-␤ARK), an inhibitor of G␤␥ signalling, or empty vector control [17] . As shown in Fig. 5(C) , ct-␤ARK expression resulted (Fig. 5D) . These results are consistent with m-SIRK pre-treatment uncoupling receptors from G␤␥ thus inhibiting the response.
Role of Src family protein tyrosine kinases
G␤␥ subunits are known activators of protein tyrosine kinases [22] . (Fig. 5D) . The specific Src family tyrosine kinase inhibitor PP2 significantly inhibited the B1R agonistinduced nitric oxide release in both cytokine-treated HLMVEC and transfected HEK293 cells (Fig. 6A) . (Fig. 6A) .
We investigated the role of Src in HEK293 cells co-transfected with iNOS and B1R, with or without dominant-negative (DN)-Src cDNA. B1R agonist produced significantly less nitric oxide in cells transfected with DN-Src whereas L-Arg dependent nitric oxide release was the same
Role of components of the ERK MAPK pathway in B1R-mediated iNOS activation
Activation of the MAPK ERK typically involves upstream sequential activation of the small GTPase Ras and the kinases Raf and MEK. To determine the role of Ras, HLMVEC were transfected with dominant negative H-Ras (DN-H-Ras) and then cytokine treated. B1R agonist generated significantly lower nitric oxide release in cells transfected with DN-H-Ras (Fig. 6A). L-Arg dependent basal nitric oxide production in these cells was not affected (data not shown) and transfection itself did not decrease B1R-mediated nitric oxide output (Fig. 3A). Similarly, in HEK293 cells expressing iNOS and B1R, DN-H-Ras transfection significantly reduced B1R-mediated nitric oxide output
To determine the role of the MAP kinase Raf, cytokine treated HLMVEC or HEK293 cells transfected with iNOS and B1R were pre-incubated for 20 min. with 100 nM Raf kinase inhibitor (5-Iodo-3-[(3,5-dibromo-4-hydroxyphenyl)methylene]-2-indolinone). As shown in Fig. 6(A), Raf kinase inhibitor resulted in a substantial decrease in B1R-dependent nitric oxide, suggesting that Raf is an important component of the B1R signalling pathway. One of the main downstream targets of Raf is MEK. Pre-treatment of cells with MEK inhibitor PD98059 (20 M for 30 min.), resulted in significant inhibition of B1R-dependent nitric oxide release in both cytokine-treated HLMVEC and transfected HEK293 cells (Fig. 6B). To confirm this, we used the cell-permeable ERK activation inhibitor peptide I Ste-MPKKKPTPIQLNP-NH2 (30 M, 20 min.) that selectively binds to ERK and prevents its interaction with MEK. This inhibitor also significantly reduced B1R-dependent nitric oxide production in cytokine-treated HLMVEC and in transfected HEK293 cells (Fig. 6B). Basal L-Arg-dependent nitric oxide release (180 Ϯ 20 nM nitric oxide; n ϭ 3) was not significantly inhibited by either the ERK activation inhibitor peptide (155 Ϯ 35 nM nitric oxide; n ϭ 3) or PD98059 (185 Ϯ 20 nM nitric oxide; n ϭ 3). These data indicate that the Ras→Raf→MEK→ERK MAPK
Fig. 4 B1R-mediated iNOS activation is PTX sensitive. HLMVEC were pre-treated with cytokines and HEK293 cells were transfected with iNOS and B1R as described in 'Materials and methods'. Cells were pre-treated with PTX (1.5 g/ml) for 3 hrs. Basal Arg-mediated (A) or B1R-activated (B) iNOS-dependent nitric oxide production was measured as described (see Fig. 3A legend and 'Materials and methods'). Data shown are mean values Ϯ S.E.M for n ϭ 3. *P Ͻ 0.05 compared with control.
cascade is critical for B1R-dependent, but not basal, nitric oxide production by iNOS. [23] . In cytokine-treated HLMVEC, neither the PKC activator phorbol myristate acetate (1 M, 30 min.) nor PKC inhibitor calphostin C (1 M, 30 min.) had any effect on B1R agonist-induced nitric oxide output (Fig. 6C) . In HEK293 cells transfected with iNOS and B1R, the PKC inhibitor also had no effect (Fig. 6C) . The specific phosphatidylinositol 3-kinase inhibitor LY94002 (10 M, 30 min.) as well as Akt inhibitor SH-6 (25 M, 30 min.) also had no effect on B1R dependent nitric oxide output in transfected HEK293 cells (Fig. 6C) . Thus, these 
B1R-mediated iNOS activation is independent of PKC and phosphatidylinositol 3-kinase
Activation of ERK can occur by alternate pathways, for example in MCF-7 cells, bradykinin results in ERK activation by a PKC/Akt dependent pathway
Constitutively active G␣i Q204L signals through the ERK MAPK pathway
Because cells transfected with constitutively active G␣i Q204L, generated high output nitric oxide without the need for B1R activation (Fig. 5) 
B1R-mediated ERK activation depends on G␣i, Src and MEK
We previously found that ERK-mediated phosphorylation of iNOS is required for B1R-dependent high output nitric oxide production [15] . We investigated whether upstream molecules implicated in this study (i.e. G␣i, Src and MEK) mediate their effects through ERK. Activation of the B1R in cytokine-treated HLMVEC resulted in a time-dependent increase in phospho-ERK (Fig. 7) . B1R-dependent ERK activation was blocked by PTX (Fig. 7) , indicating the involvement of G␣i. Pre-treatment with the Src family tyrosine kinase inhibitor PP2 and MEK inhibitor PD98059, or pre-stimulation of ␤␥ signalling with m-SIRK to occlude the response, also inhibited B1R-mediated ERK activation (Fig. 7) . [24] to generate iNOS-derived high output nitric oxide in cytokine-treated HLMVEC [13, 14] . ACE inhibitors also stimulate B1R-dependent high-output nitric oxide production in bovine pulmonary artery endothelial cells although the signalling pathways activated appear to differ from those activated by peptide agonist [13] . In cytokine-treated HLMVEC, 100 nM ACE inhibitor enalaprilat stimulated high output nitric oxide production equivalent to that generated by 100 nM B1R peptide agonist DAKD (Fig. 8) . The nitric oxide output was B1R and iNOS-dependent as it was blocked by the specific B1R antagonist DALKD or by iNOS-specific inhibitor 1400 W, but not by B2 receptor antagonist HOE140 (Fig. 8) . As with the peptide agonist, the signalling pathway stimulated by ACE inhibitor depended on activation of G␣i and MEK/ERK as it was inhibited by PTX or PD98059 (Fig. 8) 
Angiotensin converting enzyme inhibitor generates iNOS-dependent high output nitric oxide through the B1R-G␣i-MAPK pathway
ACE inhibitors can act as direct B1R agonists
Discussion
Kinin peptides generated by the kallikrein-kinin system regulate renal and cardiovascular functions by activating two G-protein coupled receptors, named B1 and B2 [25] . B2R signal transduction has been the focus of many studies, but B1R signalling is less well characterized. Both receptors couple to G␣q/11 and G␣i/o, but have unique peptide agonists and are regulated differentially at the level of receptor expression and desensitization [19] . The B2R is constitutively expressed in many cell types but expression of the B1R is induced in response to injury or inflammatory mediators [19] . Bradykinin by carboxypeptidase M and carboxypeptidase N, [26] . We recently showed that the membrane carboxypeptidase M binds to B1Rs on the cell surface to form a signalling complex required for efficient B1R signalling in response to bradykinin or kallidin [27] . The parallel but distinct B1R and B2R signalling pathways extend to activation of nitric oxide synthases. The B2R activates the constitutively expressed eNOS [28] , but we found that the B1R specifically activates iNOS in human endothelial cells [13, 15] , whose expression is induced under the same inflammatory conditions as the B1R [5, 19] . In other studies on endothelial cells or transfected HEK cells, we found no evidence for activation of eNOS by B1Rs [15] or activation of iNOS by B2Rs (Zhang Y, Lowry J, Brovkovych V, Skidgel, RA, unpublished) .
iNOS was considered to be regulated primarily at the level of expression [1, [4] [5] [6] [27] . Thus, the B1R-iNOS pathway may play important roles in inflammation where B1R signalling can have both deleterious and beneficial effects [19, 32, 33] . For example, B1R knockout protected mice from LPS-induced hypotension, reduced pain in response to thermal or chemical stimuli as well as neuropathic pain, and reduced intestinal ischemia/reperfusion injury and lethality [33] . However, B1R signalling is also beneficial, for example in protecting kidneys from ischemia/reperfusion injury [34] , promoting vasodilation, angiogenesis and neovascularization during wound healing [33] , and reducing lethality in a porcine model of endotoxic shock [35] .
The B1R may also participate in the protective effects of ACE inhibitors in heart disease and diabetes [36] [37] [38] . One way ACE Fig. 9 
